Clinical trial · Observational
PET Evaluation of Response After 1 Course of Chemotherapy as Predictor of Treatment Outcome.
Evaluation of Prognostic and Predictive Value of PETSCAn in ColoRectal Cancer (CRC)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Study hypothesis : early decrease in fdg-pet measured SUV max after 1 cycle of chemotherapy can accurately predict response of chemotherapy as assessed by conventional radiology after 3 cycles of chemotherapy. FDG-PET imaging will be done at J0 and J14 of a new line of chemotherapy treatment in metastatic colorectal cancer. SUV max will be recorded and delta SUVmax will be compared to the results of conventional radiological evaluation after 3 courses of chemotherapy. Results will also be compared to the time to disease progression.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer Metastatic | Colorectal Neoplasm | PROBABILISTIC | 0.70 |
| Early Response Evaluation | — | UNRESOLVED | — |
| Fdg-PET | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FDG-PET imaging | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- 1
- description
- all study population
- interventionNames
- Procedure: FDG-PET imaging
Primary outcomes (1)
- measure
- compare fdg-pet variations after 1 course of chemotherapy to chemotherapy outcome measured by time to disease progression
- timeFrame
- Time to Disease progression
Secondary outcomes (1)
- measure
- compare fdg-pet variations after 1 course of chemotherapy to chemotherapy outcome measured by tumour response rate following RECIST criteria.
- timeFrame
- response rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * advanced colorectal cancer * evaluable disease * signed informed consent Exclusion Criteria: * no other cancer * no other life-threatening condition * unwillingness or inability to sign informed consent * active cerebral metastasis
References
Publications (0)
Data not yet available